Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 2.2024

被引：8

作者：

Wierda, William G. ^{[1
]}

Brown, Jennifer ^{[2
]}

Abramson, Jeremy S. ^{[3
]}

Awan, Farrukh ^{[4
]}

Bilgrami, Syed F. ^{[5
]}

Bociek, Greg ^{[6
]}

Brander, Danielle ^{[7
]}

Cortese, Matthew ^{[8
]}

Cripe, Larry ^{[9
]}

Davis, Randall S. ^{[10
]}

Eradat, Herbert ^{[11
]}

Fakhri, Bita ^{[12
]}

Fletcher, Christopher D. ^{[13
]}

Gaballa, Sameh ^{[14
]}

Hamid, Muhammad Saad ^{[15
]}

Hill, Brian ^{[16
]}

Kaesberg, Paul ^{[17
]}

Kahl, Brad ^{[18
]}

Kamdar, Manali ^{[19
]}

Kipps, Thomas J. ^{[20
]}

Ma, Shuo ^{[21
]}

Mosse, Claudio ^{[22
]}

Nakhoda, Shazia ^{[23
]}

Parikh, Sameer ^{[24
]}

Schorr, Andrew

Schuster, Stephen ^{[25
]}

Seshadri, Madhav ^{[26
]}

Siddiqi, Tanya ^{[27
]}

Stephens, Deborah M. ^{[28
]}

Thompson, Meghan ^{[29
]}

Ujjani, Chaitra ^{[30
]}

Valdez, Riccardo ^{[31
]}

Wagner-Johnston, Nina ^{[32
]}

Woyach, Jennifer A. ^{[33
]}

Sundar, Hema ^{[34
]}

Dwyer, Mary ^{[34
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

[3] Mass Gen Canc Ctr, Waltham, MA USA

[4] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[5] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[6] Fred & Pamela Buffett Canc Ctr, Omaha, NE 68105 USA

[7] Duke Canc Inst, Durham, NC USA

[8] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[9] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[10] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[11] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[12] Stanford Canc Inst, Stanford, CA 94305 USA

[13] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[15] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN USA

[16] Cleveland Clin, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Taussing Canc Inst, Cleveland, OH USA

[17] Uc Davis Comprehens Canc Ctr, Davis, AL USA

[18] Washington Univ, Barnes Jewish Hosp, Siteman Canc Ctr, Sch Med, Washington, DC USA

[19] Univ Colorado, Canc Ctr, Aurora, CO 80112 USA

[20] UC San Diego Moores Canc Ctr, La Jolla, CA USA

[21] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[22] Vanderbilt Ingram Canc Ctr, Vanderbilt, TN 37232 USA

[23] Fox Chase Canc Ctr, Oreland, PA USA

[24] Mayo Clin, Comprehens Canc Ctr, Rochester, MN USA

[25] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[26] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[27] City Hope Natl Med Ctr, Duarte, CA USA

[28] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[29] Mem Sloan Kettering Canc Ctr, New York, NY USA

[30] Fred Hutchinson Canc Ctr, Seattle, WA USA

[31] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[32] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA

[33] Ohio State Univ, Solove Res Inst, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA

[34] Natl Comprehens Canc Network, Rockledge, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2024年 / 22卷 / 03期

关键词：

MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; HIGH-DOSE METHYLPREDNISOLONE; PROGRESSION-FREE SURVIVAL; PREVIOUSLY UNTREATED PATIENTS; CLINICAL END-POINTS; TERM-FOLLOW-UP; V-H GENES; OPEN-LABEL; PHASE-II;

D O I：

10.6004/jnccn.2024.0018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identi fied. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent 's toxicity pro file. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.

引用

页码：175 / 204

页数：30

共 50 条

[31] Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia
Abou Zahr, Abdallah
Bose, Prithviraj
Keating, Michael J.
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (09) : 857 - 873
[32] Chronic lymphocytic leukemia
Hallek, Michael
Pflug, Natali
ANNALS OF ONCOLOGY, 2010, 21 : 154 - 164
[33] Update on Therapy of Chronic Lymphocytic Leukemia
Gribben, John G.
O'Brien, Susan
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 544 - 550
[34] Current Treatment of Chronic Lymphocytic Leukemia
Jamroziak, Krzysztof
Pula, Bartosz
Walewski, Jan
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
[35] Ibrutinib for the treatment of chronic lymphocytic leukemia
Deodato, Marina
Frustaci, Anna Maria
Zamprogna, Giulia
Cairoli, Roberto
Montillo, Marco
Tedeschi, Alessandra
EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (05) : 273 - 284
[36] Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Strati, Paolo
Jain, Nitin
O'Brien, Susan
MAYO CLINIC PROCEEDINGS, 2018, 93 (05) : 651 - 664
[37] Predicting survival in chronic lymphocytic leukemia
Bazargan, Ali
Tam, Constantine S.
Keating, Michael J.
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (03) : 393 - 403
[38] Therapeutic advancement of chronic lymphocytic leukemia
Lu, Kang
Wang, Xin
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
[39] Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, Michael
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (09) : 946 - 965
[40] Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Hallek, Michael
AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 450 - 480

← 1 2 3 4 5 →